970 reports of this reaction
2.2% of all AFLIBERCEPT reports
#13 most reported adverse reaction
EYE INFLAMMATION is the #13 most commonly reported adverse reaction for AFLIBERCEPT, manufactured by Regeneron Pharmaceuticals, Inc.. There are 970 FDA adverse event reports linking AFLIBERCEPT to EYE INFLAMMATION. This represents approximately 2.2% of all 43,844 adverse event reports for this drug.
Patients taking AFLIBERCEPT who experience eye inflammation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EYE INFLAMMATION is a less commonly reported adverse event for AFLIBERCEPT, but still significant enough to appear in the safety profile.
In addition to eye inflammation, the following adverse reactions have been reported for AFLIBERCEPT:
The following drugs have also been linked to eye inflammation in FDA adverse event reports:
EYE INFLAMMATION has been reported as an adverse event in 970 FDA reports for AFLIBERCEPT. This does not prove causation, but indicates an association observed in post-market surveillance data.
EYE INFLAMMATION accounts for approximately 2.2% of all adverse event reports for AFLIBERCEPT, making it a notable side effect.
If you experience eye inflammation while taking AFLIBERCEPT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.